Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Drugs of Today (Barcelona, Spain : 1998)|November 22, 2012
Vandetanib therapy in medullary thyroid cancerP Grabowski, F Briest, R P Baum, et al.
Minerva Gastroenterologica E Dietologica|December 5, 2012
Pancreatic neuroendocrine neoplasmsD Hörsch, T Bert, J Schrader, et al.
Diabetologia|April 20, 2007
Cytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell deathJ Schrader, W Rennekamp, U Niebergall, et al.
Molecular Cell|December 9, 1998
A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose toleranceJ C Brüning, M D Michael, J N Winnay, et al.
Pneumologie (Stuttgart, Germany)|July 10, 2014
[Pulmonary neuroendocrine neoplasms]Y Sayeg, M Sayeg, R P Baum, et al.
Clinical & Experimental Metastasis|August 8, 2014
The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasmD Kaemmerer, N Posorski, F von Eggeling, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 8, 2013
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursL Bodei, J Mueller-Brand, R P Baum, et al.
Endocrine-Related Cancer|June 24, 2024
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET studyE Baudin, J Capdevila, D Hörsch, et al.
Nuklearmedizin. Nuclear Medicine|February 17, 2015
[Peptide receptor radionuclide therapy for patients with somatostatin receptor expressing tumours. German Guideline (S1)]T D Poeppel, C Boy, A Bockisch, et al.
Der Pathologe|March 28, 2014
[Neuroendocrine neoplasms of the distal jejunum and ileum]M Anlauf, B Sipos, I Boeck, et al.
Pageof 4